Your search history is turned on.
Date: April 22, 2024 Jurisdictions: Quebec
Microsoft Word - AMENDED - MilestonePharmaceutical NOMRD_French.doc Le 22 avril 2024 650 boul. de Maisonneuve O. 7e tage Montral (Qubec), H3A 3T2 www.computershare.com Destinataires: Toutes les autorits canadiennes en valeurs mobilires AVIS AMEND Objet: Milestone Pharmaceutiques inc. Madame, Monsieur, ...
Microsoft Word - AMENDED - MilestonePharmaceutical NOMRD_English.doc April 22, 2024 650 de Maisonneuve Blvd W. 7th Floor Montreal QC, H3A 3T2 www.computershare.com To: All Canadian Securities Regulatory Authorities AMENDED NOTICE Subject: MILESTONE PHARMACEUTICALS INC. Dear Sir/Madam: We advise of th...
Date: April 9, 2024 Jurisdictions: Quebec
sec.gov/Archives/edgar/data/1408443/000110465924044767/tm2411306d1_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of registrant as speci...
sec.gov/Archives/edgar/data/1408443/000110465924044767/tm2411306d1_ex99-1.htm Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting Data from this large safety-trial also published in The Journal of the American College of Cardiology Montreal and Charlott...
Date: March 28, 2024 Jurisdictions: Quebec
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia Montreal and Charlotte, N.C., March 28, 2024 -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmi...
Date: March 26, 2024 Jurisdictions: Quebec
Microsoft Word - MilestonePharmaceutical NOMRD_French.doc Le 26 mars 2024 650 boul. de Maisonneuve O. 7e tage Montral (Qubec), H3A 3T2 www.computershare.com Destinataires: Toutes les autorits canadiennes en valeurs mobilires Objet: Milestone Pharmaceutiques inc. Madame, Monsieur, Veuillez prendre note des informations r...
Microsoft Word - MilestonePharmaceutical NOMRD_English.doc March 26, 2024 650 de Maisonneuve Blvd W. 7th Floor Montreal QC, H3A 3T2 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: MILESTONE PHARMACEUTICALS INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holde...
Date: March 21, 2024 Jurisdictions: Quebec
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 MILESTONE PHARMACEUTICALS INC. (Exact name of regist...
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Amit Hasija, certify that: 1. I have reviewed this Annual Report on Form 10-K of Milestone Pharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain an...
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Oliveto, certify that: 1. I have reviewed this Annual Report on Form 10-K of Milestone Pharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain...